歌礼制药有限公司（股票代码：1672）于2026年3月3日发布截至2026年2月28日的股份变动月报表。公告显示，公司法定股本本月未变动，仍为70亿股授权股本，每股面值0.0001美元，总额700,000美元。
报告期内，公司已发行股份（不含库存股）数由上月底的991,874,320股增至1,061,130,320股，期间变动主要来自于2月10日完成的配售发行，涉及69,256,000股新股。库存股数量保持在7,084,210股。截至2月底，公司已发行股份总数为1,068,214,530股。其中，于2025年及更早完成的合计约5,786,000股回购股份尚未注销。
公司同时披露了购回与期权等事宜。根据公告，报告期内无来自股份期权的新增发行或行使，未见有其他股份期权或可转换证券的变动。公司确认已满足香港联交所规则对公众持股量的要求。
截至报告期末，公司已发行股份总数增至约10.68亿股。公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.